RJA
ZVRA icon

Raymond James & Associates’s Zevra Therapeutics ZVRA Stock Holding History

Raymond James & Associates’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,114
Closed -$141K – 3682
2018
Q1 		$141K Buy
+1,114
New +$108K ﹤0.01% 3221

Other funds holding ZVRA

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Raymond James & Associates's ZVRA Position: Q2 2018 in Review

Raymond James & Associates sold out of Zevra Therapeutics (ZVRA) in Q2 2018, closing a stake of 1,114 shares — an estimated $141K sold.

Raymond James & Associates first reported a position in ZVRA in Q1 2018 and held it in 1 quarter. The position peaked at $141K in Q1 2018. 40 funds tracked by Wall St. Rank hold ZVRA as of Q2 2018.

  • Raymond James & Associates reported no remaining Zevra Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Raymond James & Associates sold 1,114 Zevra Therapeutics shares in Q2 2018, an estimated $141K.
  • Raymond James & Associates first reported a position in Zevra Therapeutics in Q1 2018 and held it in 1 quarter.
  • Raymond James & Associates's Zevra Therapeutics position peaked at $141K in Q1 2018.
  • 40 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2018.

Based on Raymond James & Associates's 13F filing for Q2 2018, filed 14 Aug 2018.